IND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully...
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...
Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program Completed public...
Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...
Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...
Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...
Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest...
WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for...